600521.SS · 华海药业
China A-shares · RS rating 77 · As of 2026-10-14
| Price | 16.50 CNY |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 77 / 89 / 54 / 31 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 30 / 26 / 18 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +10.4% |
| Distance from 52-week high | +26.1% |
| Market cap (USD) | $3.7B |